This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
billion by 2026. Jazz Pharmaceuticals has introduced a new prescription medication for patients with sleep apnea/narcolepsy that “helped adults get up to 9 hours of improved wakefulness in clinical studies at 12 weeks” and they’re using a flying pig on their DTC. This DTC is an embaressment.
It has demonstrated improvements in cognition and is not associated with common sideeffects of currently approved treatments like weight gain. The drug is also undergoing trials both for adjunctive therapy to existing standard of care agents in schizophrenia and for the treatment of psychosis in patients with Alzheimer’s disease.
Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as possible to patients in the world’s second-largest pharma market. It is being tested in a wide range of solid tumours and lymphoma, alone and in combination with other drugs.
This was following a dogged advocacy campaign from ALS clinicians and patients, and the release of additional AMX0035 data. Dr Merit Cudkowicz, a co-principal investigator in Amylyx’s clinical trials, says patients and investigators are pushing for an approval given the unmet need for therapies. “By The FDA’s action plan.
That will fund operations until 2026, beyond the readout of phase 3 trials including the BROADWAY study of obicetrapib in adults with heterozygous familial hypercholesterolaemia (HeFH) and/or established atherosclerotic cardiovascular disease (ASCVD) who can’t control LDL cholesterol on statin drugs alone.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content